These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 6927209)

  • 1. Transdermal scopolamine in motion sickness.
    Cronin CM; Sallan SE; Wolfe L
    Pharmacotherapy; 1982; 2(1):29-31. PubMed ID: 6927209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of transdermal scopolamine on motion sickness during 7 days' exposure to heavy seas.
    van Marion WF; Bongaerts MC; Christiaanse JC; Hofkamp HG; van Ouwerkerk W
    Clin Pharmacol Ther; 1985 Sep; 38(3):301-5. PubMed ID: 4028625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of transdermally administered scopolamine in preventing motion sickness.
    McCauley ME; Royal JW; Shaw JE; Schmitt LG
    Aviat Space Environ Med; 1979 Nov; 50(11):1108-11. PubMed ID: 393242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transdermal scopolamine delivery system (TRANSDERM-V) and acute angle-closure glaucoma.
    Hamill MB; Suelflow JA; Smith JA
    Ann Ophthalmol; 1983 Nov; 15(11):1011-2. PubMed ID: 6651138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transdermal scopolamine in the prevention of motion sickness: evaluation of the time course of efficacy.
    Homick JL; Kohl RL; Reschke MF; Degioanni J; Cintron-Trevino NM
    Aviat Space Environ Med; 1983 Nov; 54(11):994-1000. PubMed ID: 6651736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications.
    Nachum Z; Shupak A; Gordon CR
    Clin Pharmacokinet; 2006; 45(6):543-66. PubMed ID: 16719539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transdermal scopolamine for motion sickness.
    Med Lett Drugs Ther; 1981 Oct; 23(21):89-90. PubMed ID: 7027000
    [No Abstract]   [Full Text] [Related]  

  • 8. The efficacy of low-dose intranasal scopolamine for motion sickness.
    Simmons RG; Phillips JB; Lojewski RA; Wang Z; Boyd JL; Putcha L
    Aviat Space Environ Med; 2010 Apr; 81(4):405-12. PubMed ID: 20377145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of experimental motion sickness by scopolamine absorbed through the skin.
    Graybiel A; Knepton J; Shaw J
    Aviat Space Environ Med; 1976 Oct; 47(10):1096-100. PubMed ID: 791234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accidental mydriasis from scopolamine patches.
    Rosen NB
    J Am Optom Assoc; 1986 Jul; 57(7):541-2. PubMed ID: 3745760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of TTS-scopolamine, dimenhydrinate, lidocaine, and tocainide on motion sickness, vertigo, and nystagmus.
    Pyykkö I; Padoan S; Schalén L; Lyttkens L; Magnusson M; Henriksson NG
    Aviat Space Environ Med; 1985 Aug; 56(8):777-82. PubMed ID: 3929760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of motion sickness in parabolic flight with buccal scopolamine.
    Norfleet WT; Degioanni JJ; Calkins DS; Reschke MF; Bungo MW; Kutyna FA; Homick JL
    Aviat Space Environ Med; 1992 Jan; 63(1):46-51. PubMed ID: 1550533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transderm scopolamine efficacy related to time of application prior to the onset of motion.
    Levy GD; Rapaport MH
    Aviat Space Environ Med; 1985 Jun; 56(6):591-3. PubMed ID: 4015572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal scopolamine, oral meclizine, and placebo in motion sickness.
    Dahl E; Offer-Ohlsen D; Lillevold PE; Sandvik L
    Clin Pharmacol Ther; 1984 Jul; 36(1):116-20. PubMed ID: 6734040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transdermal scopolamine in the prevention of motion sickness at sea.
    Price NM; Schmitt LG; McGuire J; Shaw JE; Trobough G
    Clin Pharmacol Ther; 1981 Mar; 29(3):414-9. PubMed ID: 7009021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transdermal scopolamine intoxication in a child.
    Klein BL; Ashenburg CA; Reed MD
    Pediatr Emerg Care; 1985 Dec; 1(4):208-9. PubMed ID: 3842169
    [No Abstract]   [Full Text] [Related]  

  • 17. Transdermal therapeutic system scopolamine (TTSS), dimenhydrinate, and placebo--a comparative study at sea.
    Noy S; Shapira S; Zilbiger A; Ribak J
    Aviat Space Environ Med; 1984 Nov; 55(11):1051-4. PubMed ID: 6508687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transdermal scopolamine use in the control of narcotic-induced nausea.
    Ferris FD; Kerr IG; Sone M; Marcuzzi M
    J Pain Symptom Manage; 1991 Aug; 6(6):389-93. PubMed ID: 1880439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histaminergic response to Coriolis stimulation: implication for transdermal scopolamine therapy of motion sickness.
    Wang ET; Zhou DR; He LH
    Aviat Space Environ Med; 1992 Jul; 63(7):579-82. PubMed ID: 1616432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics in clinical use of scopolamine.
    Renner UD; Oertel R; Kirch W
    Ther Drug Monit; 2005 Oct; 27(5):655-65. PubMed ID: 16175141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.